Characterizing the Relationship Between Arterial Carbon Dioxide Trajectory and Serial Brain Biomarkers with Central Nervous System Injury During Veno-Venous Extracorporeal Membrane Oxygenation: A Prospective Cohort Study

Sonny Thiara,Sophie Stukas,Ryan Hoiland,Cheryl Wellington,Mike Tymko,George Isac,Gordon Finlayson,Hussein Kanji,Kali Romano,Veronica Hirsch-Reinshagen,Mypinder Sekhon,Donald Griesdale

DOI: https://doi.org/10.1007/s12028-023-01923-x

2024-02-04

Neurocritical Care

Abstract:Central nervous system (CNS) injury following initiation of veno-venous extracorporeal membrane oxygenation (VV-ECMO) is common. An acute decrease in partial pressure of arterial carbon dioxide (PaCO 2 ) following VV-ECMO initiation has been suggested as an etiological factor, but the challenges of diagnosing CNS injuries has made discerning a relationship between PaCO 2 and CNS injury difficult.

clinical neurology,critical care medicine

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether the sharp decline in arterial partial pressure of carbon dioxide (PaCO2) is related to central nervous system (CNS) injury during the treatment of acute respiratory failure with veno - venous extracorporeal membrane oxygenation (VV - ECMO). Specifically, the study aims to explore the following three main objectives:

1. **The relationship between PaCO2 decline and CNS injury**: The researchers hypothesized that the rapid decline in PaCO2 before and after the initiation of VV - ECMO may be related to the occurrence of CNS injury. This relationship was evaluated by analyzing the trajectory of PaCO2 changes in patients before and after the initiation of VV - ECMO.

2. **The relationship between brain injury biomarkers and CNS injury**: The researchers also hypothesized that the levels of nerve injury biomarkers in the blood (such as neurofilament light chain protein [NF - L], glial fibrillary acidic protein [GFAP], and phosphorylated tau protein [p - tau 181]) would be significantly increased in patients with CNS injury. The relationship between these biomarkers and CNS injury was evaluated by measuring their levels.

3. **The effect of PaCO2 changes on brain injury biomarkers**: As an exploratory analysis, the researchers further explored whether changes in PaCO2 would affect the levels of these brain injury biomarkers. The researchers hypothesized that a greater decrease in PaCO2 might lead to an increase in the levels of these biomarkers.

### Research background
- **Application of VV - ECMO**: VV - ECMO is a technique used to treat acute respiratory failure. It performs gas exchange through an extracorporeal circulation system and reduces lung injury caused by mechanical ventilation.
- **Risk of CNS injury**: Although VV - ECMO can save lives, its use is associated with multiple complications, especially CNS injury (such as intracranial hemorrhage or ischemic infarction), which can lead to higher mortality and poor long - term functional outcomes.
- **Potential mechanisms of PaCO2 decline**: A sharp decline in PaCO2 may lead to cerebral vasoconstriction and cerebral hypoperfusion, thereby aggravating CNS injury.

### Methods
- **Study design**: A prospective cohort study, including 59 adult patients receiving VV - ECMO treatment.
- **Data collection**: Arterial blood gas samples were collected every 2 - 4 hours within 24 hours before and after the initiation of VV - ECMO, and PaCO2 values were recorded. At the same time, blood samples were collected to measure the levels of NF - L, GFAP, and p - tau 181.
- **Statistical analysis**: A mixed - effects linear regression model was used to analyze the relationship between PaCO2 changes and CNS injury, as well as the relationship between brain injury biomarker levels and CNS injury.

### Results
- **Incidence of CNS injury**: 12 patients (20%) developed CNS injury after the initiation of VV - ECMO.
- **PaCO2 changes and CNS injury**: The PaCO2 in patients with CNS injury decreased more rapidly (−0.32%, 95% confidence interval −0.25 to −0.39), while the PaCO2 in patients without CNS injury decreased more slowly (−0.18%, 95% confidence interval −0.14 to −0.21).
- **Brain injury biomarkers**: The levels of NF - L and GFAP in patients with CNS injury were significantly higher than those in patients without CNS injury. However, there was no significant difference in the p - tau 181 level between the two groups.
- **The effect of PaCO2 changes on biomarkers**: There was no significant difference in the levels of brain injury biomarkers under different PaCO2 change thresholds.

### Conclusion
Although the sharp decline in PaCO2 was more obvious in patients with CNS injury, the data overlap and the lack of a relationship between PaCO2 and brain injury biomarkers suggest that other pathophysiological factors may also be at work. Future research needs to further explore these complex relationships to better understand the mechanisms of VV - ECMO - related CNS injury.